Earnings
EBIT and EBITDA
Earnings before interest and tax (EBIT) improved year on year to reach €414.8 million (€137.6 million). EBIT included budgeted negative effects from purchase price allocations totaling €41.8 million (H1 2020: €44.8 million). Non-recurring items amounting to an expense of €5.5 million were also recognized in the period under review and related in part to the capacity and structural program. The prior-year figure, an expense of €22.3 million, mainly included components of the capacity and structural program as well as an impairment charge on an equity investment. Earnings before interest and tax adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) amounted to €462.2 million for the first six months of 2021, which was more than double the figure for the first half of 2020 of €204.8 million. The adjusted EBIT margin recovered to 9.3 percent (H1 2020: 5.2 percent).
in € million |
Q2 |
Q2 |
Q1 – Q2 |
in % of revenue |
Q1 – Q2 |
in % of revenue |
---|---|---|---|---|---|---|
EBIT |
221.3 |
17.5 |
414.8 |
8.4% |
137.6 |
3.5% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
9.4 |
10.3 |
18.9 |
0.4% |
20.3 |
0.5% |
+ Selling expenses and administrative expenses |
15.1 |
22.0 |
29.5 |
0.6% |
35.7 |
0.9% |
+ Research and development costs |
0.0 |
0.0 |
0.1 |
0.0% |
0.1 |
0.0% |
+ Other costs |
1.4 |
10.9 |
–1.1 |
0.0% |
11.0 |
0.3% |
Adjusted EBIT |
247.2 |
60.7 |
462.2 |
9.3% |
204.8 |
5.2% |
adjusted for non-recurring items |
5.0 |
20.6 |
5.5 |
0.1% |
22.3 |
0.6% |
adjusted for PPA items |
20.9 |
22.7 |
41.8 |
0.8% |
44.8 |
1.1% |
Earnings before interest, tax, depreciation, and amortization (EBITDA) rose to €873.9 million (H1 2020: €597.1 million). Adjusted EBITDA increased to €879.5 million (H1 2020: €619.4 million), giving an adjusted EBITDA margin of 17.7 percent (H1 2020: 15.8 percent).
in € million |
Q2 |
Q2 |
Q1 – Q2 |
in % of revenue |
Q1 – Q2 |
in % of revenue |
---|---|---|---|---|---|---|
EBITDA |
452.7 |
247.8 |
873.9 |
17.6% |
597.1 |
15.2% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
0.0 |
–0.1 |
0.0 |
0.0% |
–0.1 |
0.0% |
+ Selling expenses and administrative expenses |
3.6 |
9.8 |
6.6 |
0.1% |
11.4 |
0.3% |
+ Research and development costs |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |
+ Other costs |
1.4 |
10.9 |
–1.0 |
0.0% |
11.0 |
0.3% |
Adjusted EBITDA |
457.7 |
268.4 |
879.5 |
17.7% |
619.4 |
15.8% |
adjusted for non-recurring items |
5.0 |
20.6 |
5.6 |
0.1% |
22.3 |
0.6% |
adjusted for PPA items |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |
EBITDA for the long-term leasing business, which is derived from internal reporting and assumes a minimum rate of return on the capital employed, amounted to €170.0 million in the reporting period (H1 2020: €167.7 million).